Company (location)

Type of financing

Number of shares, units or warrants (M)

Amount raised (US$M)

Investors; placement agents; details

Date

Total: $463.97M

Adial Pharmaceuticals Inc. (Charlottesville, Va.)

Warrant exercise

W for 0.233S

$1.20

$1.2M from the voluntary exercise of previously outstanding warrants to purchase 243,100 shares of its common stock; additionally, 125,000 shares were issued as part of the cashless exercise of warrants

1/25/19

Aimmune Therapeutics Inc. (Brisbane, Calif.)

Equity investment

N/A

$40.00

Aimmune entered a $170 M loan agreement with an affiliate of KKR, a global investment firm; the loan will be advanced in three tranches with $40M funded at close, and $85M to follow upon FDA approval of AR-101 and satisfaction of other customary borrowing conditions; the remaining $45M will be at the company's option in 2020 upon the satisfaction of certain borrowing conditions

1/7/19

Alpine Immune Sciences Inc. (Seattle)

Private placement of common stock and warrants

4.7S and W for 1.8S

$25.30

$25.3M through the private placement of 4.7M shares and warrants to purchase 1.8M shares at a purchase price per unit of $5.37, led by Decheng Capital with participation from existing investors Orbimed Advisors, Frazier Healthcare Partners, Alpine Bioventures and BVF Partners LP; Piper Jaffray & Co. acted as sole placement agent

1/17/19

Arch Biopartners Inc. (Toronto)

Convertible note financing

N/A

$0.38

CA$500,000 (US$374,771) through a nonbrokered, unsecured convertible note financing

1/25/19

Axsome Therapeutics Inc. (New York)

At-the-market offering

2.88S

$23.30

$23.3M through the sale of 2.88M shares under its existing at-the-market (ATM) facility with Leerink Partners LLC

1/9/19

Bio-Path Holdings Inc. (Houston)

Registered direct offering and private placement

0.648S and W for 0.324S

$1.70

$1.7M registered direct offering of 648,302 shares of common stock at $2.65 per share; in a concurrent private placement, it is also issuing warrants to purchase up to 324,151 shares; H.C. Wainwright & Co. is exclusive placement agent; the company also closed a public offering of 8.6M shares priced at 13 cents each for proceeds of about $1.1M

1/22/19

Can-Fite Biopharma Ltd. (Petach Tikva, Israel)

Private placement

2.2ADS

$2.35

$2.35M through the placement of 2.2M American depositary shares at $1.05 apiece with a single institutional investor; H.C. Wainwright & Co. is acting as the exclusive placement agent

1/22/19

Coherus Biosciences Inc. (Redwood City, Calif.; CHRS)

Credit facility

N/A

$75.00

Entered $75M senior secured credit facility agreement with Healthcare Royalty Partners

1/7/19

Correvio Pharma Corp. (Vancouver, British Columbia)

At-the-market offering

4.3S

$11.65

$11.65M through an at-the-market offering of 4.3M shares at an average price of $2.71 each

1/18/19

Esperite NV (Amsterdam)

Private placement of convertible notes

N/A

$0.26

0.23 (US$0.264) in a private placement of convertible notes, which included share subscription warrants attached; this is the 24th tranche of investments under a 2017 agreement with European Select Growth Opportunities Fund

1/11/19

Immunogen Inc. (Waltham, Mass.)

Royalty sale

N/A

$65.00

$65M through a sale of its residual rights to receive royalty payments on sales of Kadcyla (ado-trastuzumab emtansine, Roche Holding AG) to Ontario's municipal employees' pension plan Omers

1/9/19

Immuron Ltd. (Melbourne, Australia)

Australian government cash refund

N/A

$1.19

$1.19M cash refund from the Australian government for eligible research and development expenditure during its 2018 fiscal year

1/9/19

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda)

Private placement

2S

$36.60

$36.6M private placement of about 2M class A1 common shares to one or more existing shareholders affiliated with certain of Kiniksa's directors at a sale price equal to the price to the public in a concurrent public offering of class A common shares, which raised $48.39M

1/30/19

Mesoblast Ltd. (Melbourne, Australia)

Four-year credit facility

N/A

$15.00

$15M drawdown from its $75M credit facility with Hercules Capital Inc.

1/15/19

Midatech Pharma plc (Abingdon, U.K.)

Private placement

103.9U

$10.50

£8M (US$10.5M) through a subscription of new ordinary shares priced at 3.85 pence apiece; CMS Medical Venture Investment (HK) Ltd. and A&B (HK) Co. Ltd. have each conditionally subscribed for 103.9M units at the issue price, with each unit consisting of one new ordinary share and one warrant to subscribe for one new share

1/30/19

Motif Bio plc (London)

Warrant exercise

0.7S

$0.20

£152,626.80 (US$199,411.67) for the exercise of warrants representing 717,384 ordinary shares of 1 pence (US1.3 cents); the exercise price of warrants representing 642,384 ordinary shares was 20 pence per warrant, and the exercise price of warrants representing 75,000 ordinary shares was 32.2 pence each

1/24/19

Nicox SA (Sophia Antipolis, France)

Tranched bond financing

N/A

$22.80

20M (US$22.8M) tranched bond financing with Kreos Capital, expected to extend its cash runway into 2021

1/28/19

Outlook Therapeutics Inc. (formerly Oncobiologics Inc.; Cranbury, N.J.)

Private placement of common stock

4.3S

$4.00

Closed on the third tranche of four of its $20M private placement of common stock to Biolexis Pte Ltd., the company's largest investor, receiving $4M in cash in exchange for about 4.28M shares at 93 cents apiece; to date, the firm has received $16M

1/3/19

Pharnext SA (Paris)

Private placement

1S

$17.10

€15M (US$17.1M) financing from CB Lux via a private placement of about 1M new shares

1/24/19

Prana Biotechnology Ltd. (Melbourne, Australia)

Securities purchase agreement

N/A

$31.40

Securities purchase agreement for a lead investment by Life Biosciences LLC, of Boston, to raise up to approximately AU$44.5M (US$31.4M); it will initially invest $7.5M, with the agreement allowing the company to raise an additional $2M from other investors; a further AU$31M would be invested by Life Biosciences and other investors on exercise of short-term warrants being issued as part of the transaction

1/3/19

Precision Therapeutics Inc. (Minneapolis)

Loan and investment

0.078S

$1.00

$1M from CEO and director Carl Schwartz who provided a $950,000 loan under an amended and restated promissory note, which now covers advances of $1.3M, including a previous loan from November, and $50,000 through the purchase of 78,125 shares of the company's common stock at 64 cents per share

1/22/19

Promis Neurosciences Inc. (Toronto)

Private placement

9.56U

$1.64

CA$2.19M (US$1.64M) through a private placement of 9.56M units at CA23 cents each; each unit consists of one common share and one share purchase warrant entitling the holder to purchase one share at an exercise price of CA48 cents

1/24/19

Recro Pharma Inc. (Malvern, Pa.)

Debt funding

N/A

$40.00

Recro amended its existing credit facility with Athyrium Capital Management LP, which reinstates access to $40M in debt funding; the company had previously drawn down $60M

1/3/19

Rezolute Inc. (Redwood City, Calif.)

Preferred stock purchase agreement

N/A

$25.00

$25M preferred stock purchase agreement with Handok Inc. and Genexine Inc., two publicly traded South Korean-based pharmaceutical companies; each preferred share is priced at $5 and automatically converts into shares of the company's common stock at an implied per share price of 22 cents

1/8/19

Theralase Technologies Inc. (Toronto)

Private placement of units

4.1U

$1.40

$1.4M through a private placement of 4.1M units, consisting of a share and a warrant to buy an additional share, at 35 cents per unit

1/9/19

Trevena Inc. (Chesterbrook, Pa.)

Registered direct offering

10S

$10.00

$10M through an offering of 10M shares at $1 each to two health care-focused institutional investors

1/31/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.